Clinical trials: Radiation Safety
Urothelial Carcinoma of the Renal Pelvis and Ureter, Neoadjuvant Therapy
Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )
This is an open-label, single-arm, single-cohort, prospective clinical study evaluating neoadjuvant antibody-drug conjugate therapy combined with immunotherapy and sequential radiotherapy followed by radical surgery in patients…
- Trial name
- LUXUS0701 (NCT07720921)
- Testing
- Neoadjuvant radiotherapy, ADC + PD1 monoclonal antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University First Hospital
Central Nervous System Neoplasms, Head and Neck Neoplasms
EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients
The purpose of this study is to determine the safety of the drug EPO906 that could shrink tumors when used with radiation therapy in cancer patients.
- Trial name
- NCT00328458
- Testing
- EPO906 (epothilone B)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Radiation Exposure to Operator, Endovascular Aortic Repair
Exoskeleton vs. Standard Lead Apron in EVAR Procedures
The goal of this clinical trial is to learn whether an exoskeleton-supported radiation protection system can reduce radiation exposure and musculoskeletal strain in vascular surgeons during endovascular aortic repair procedures…
- Conditions
- Radiation Exposure to Operator, Endovascular Aortic Repair, Musculoskeletal Strain, Occupational Radiation Exposure
- Trial name
- PROTECT-EVAR (NCT07528144)
- Testing
- Exoskeleton-supported radiation protection system, Standard lead apron
- Where
- Poland
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Samodzielny Publiczny Szpital Kliniczny nr 2 PUM
Prostate Cancer
Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer
The purpose of this study is to evaluate the safety of a new drug- sorafenib, which is to be administered at the same time as standard treatment, which includes hormonal therapy and external beam radiotherapy.
- Trial name
- NCT00924807
- Testing
- Leuprolide acetate, Bicalutamide, Sorafenib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Beth Israel Medical Center
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT03889899
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Alpha Tau Medical LTD.
Patients With Non-small Cell Lung Cancer
Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC
Lung cancer is the most common cancer, accounting for 20% of cancer-related deaths worldwide. In 2015, an estimated 610,200 patients (22 per cent of cancer-related deaths) died of lung cancer.
- Trial name
- NCT04182698
- Testing
- Simultaneous chemoradiotherapy for An Luo
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Enteritis Caused by Radiation (Disorder)
Pharmacokinetics, Safety, and Tolerability of SYN-020
This is a Phase 1, single-center, open-label, single ascending dose study to assess the PK, safety, and tolerability of SYN-020 delayed release capsules administered orally to healthy adult male and female subjects with a BMI of…
- Trial name
- NCT04815993
- Testing
- SYN-020 delayed release capsule
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Theriva Biologics, Inc.
Glioma
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive…
- Trial name
- NCT01906385
- Testing
- Rhenium Liposome Treatment
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Cerenome
Cancer
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer
Study to determine the best dose of stereotactic body radiation therapy (SBRT) to be administered in combination with immunotherapy drugs including urelumab, cabiralizumab and nivolumab .
- Trial name
- C4-MOSART (NCT03431948)
- Testing
- Nivolumab, Cabiralizumab, Urelumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Chicago
HSCT, Hematologic Cancer
The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignance Patients With Extramedullary Infiltrating
Application of Stereotactic Body Radiotherapy (SBRT) Bridging to Allogeneic Hematopoietic Stem Cell Transplantation in Adult Hematological Malignance Patients with Extramedullary Lesions.
- Trial name
- NCT07456189
- Testing
- Stereotactic body radiotherapy (SBRT)
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
The Efficacy and Safety of SBRT in MPLC
The Effectiveness and Safety of SBRT in the Treatment of Patients With MPLC After Surgery (SMILE)
To prospectively evaluate the effectiveness and safety of SBRT in the treatment of residual malignant pulmonary nodules after lung cancer, and is committed to providing new treatment options for patients with multiple primary…
- Trial name
- SMILE (NCT05113017)
- Testing
- NO Intervention
- Where
- 5 sites in China
- Volunteers
- 40 people
- Sponsor
- Fang Wu
Rectal Cancer
Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy
(1) To evaluate the oncological effects of Treatment of low locally advanced rectal cancer with radiotherapy removal TNT plus neoadjuvant therapy TNT plus mode on TRG, Anal sphincter preservation surgery rate / rectal…
- Trial name
- NCT06035133
- Testing
- CapeOX + cetuximab, CapeOX + bevacizumab, radiotherapy
- Volunteers
- 213 people
- Sponsor
- Tang-Du Hospital
High Risk Prostate Carcinoma
Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy and Hormone Therapy With SpaceOAR TM for Patients With High - Risk Localized Prostate Cancer (DESAR-H)
Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patients who underwent low-fractionation curative radiation therapy and hormone therapy
- Trial name
- DESAR-H (NCT06461793)
- Testing
- Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patients
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center
Cancer, Side Effect of Drug
Radiopharmaceuticals Analysis for Detailed Insights And INternational Tracking of Safety
Little is known about cancer therapy-related radiopharmaceuticals drugs safety. Here the investigators use VigiBase (http://www.vigiaccess.org/), the World Health Organization (WHO) database of individual safety case reports, to…
- Trial name
- RADIANTS (NCT06483685)
- Testing
- Radiopharmaceuticals drugs
- Where
- France
- Volunteers
- 500,000 people
- Sponsor
- University Hospital, Caen
ccRCC, Renal Cell Carcinoma (Kidney Cancer)
Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Multicenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC).
- Conditions
- ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic
- Trial name
- LUTEON (NCT07197580)
- Testing
- 177Lu-TLX250
- Where
- 5 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Head and Neck Cancer, Recurrent Cancer
Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer
Our preclinical study confirmed that copper accumulation can lead to radioresistance in vitro and in vivo, and reducing the concentration of copper with copper chelator help to overcome radioresistance.
- Trial name
- NCT06103617
- Testing
- Penicillamine
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Glioblastoma Multiforme
FET-PET Directed Simultaneous In-field Boost for Primary GBM
The combination of anatomical MRI examination with functional examination of tissue metabolic activity such as FET-PET (PET using the radiotracer - 18F-fluoro-ethyl-tyrosine) is a valuable tool to determine the actual tumor…
- Trial name
- dualFETboost (NCT04790097)
- Testing
- Moderately Hypofractionated Radiotherapy using Simultaneous In-Field Boost
- Where
- Poland
- Volunteers
- 17 people
- Sponsor
- Prof. Franciszek Lukaszczyk Memorial Oncology Center
Malignant Breast Neoplasm
Efficacy and Safety of Ultra_HYPofractionated RadiotHerapy in Women With BrEast CaNcer Receiving Regional Nodal Radiation vs Nodal Moderate Hypofractionated Radiotherapy
The reduction in the number of fractions in radiotherapy is especially attractive in several senses, and even more so considering breast cancer, which has a high incidence and generally favorable prognosis.
- Trial name
- HYPHEN (NCT05665920)
- Testing
- Ultra-hypofractionated whole breast radiotherapy, Standard Radiation
- Where
- Brazil
- Volunteers
- 36 people
- Sponsor
- Instituto Brasileiro de Controle do Cancer
Radiation Pneumonitis
Hyperbaric Oxygen in the Prevention of Radiation Pneumonitis
Radiotherapy is one of the important treatments to improve the survival rate of breast cancer patients, but also has the risk of radiation lung injury, which can develop into pulmonary fibrosis.
- Trial name
- NCT05189496
- Testing
- hyperbaric oxygen therapy
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Guangdong Provincial People's Hospital
Unresectable Hepatocellular Carcinoma
A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
This clinical trial was designed to evaluate the safety and efficacy of Y90-SIRT combined with nivolumab, ipilimumab, and lenvatinib in patients with unresectable HCC.
- Trial name
- NCT07482059
- Testing
- ttrium-90 microspheres in combination with nivolumab, ipilimumab, and lenvatinib in patients with unresectable hepatocellular carcinoma
- Where
- China
- Volunteers
- 33 people
- Sponsor
- West China Hospital